Gilead Sciences | Bienes

Precio De Mercado
151.40
Cambio Diario
0.28 0.19%
Mensual
17.26%
Anual
37.70%
Q1 Expectativa
146.71




Bienes Cambio Fecha
AbbVie USD 133.96B 62M 2025-12
Agios Pharmaceuticals USD 1.3B 88.48M 2025-12
ALKERMES USD 2.33B 76.7M 2025-09
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amgen USD 90.59B 445M 2025-12
Biogen USD 29.44B 232M 2025-12
BioMarin Pharmaceutical USD 7.61B 158.53M 2025-09
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Coherus Biosciences USD 516.52M 77.05M 2025-09
Eli Lilly USD 112.48B 2.46B 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Glaxosmithkline GBP 82.45B 23.19B 2025-09
Incyte USD 6.96B 627.62M 2025-12
J&J USD 199.21B 6.39B 2025-12
Merck USD 129.55B 12.02B 2025-09
Moderna USD 12.34B 203M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Novartis USD 107.29B 2.89B 2025-09
Pfizer USD 208.73B 2.64B 2025-09
PTC Therapeutics USD 2.9B 255.07M 2025-12
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 126.81B 2.99B 2025-12
Sarepta Therapeutics USD 3.49B 186.38M 2025-09
United Therapeutics USD 7.35B 556.9M 2025-09
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12


Gilead Sciences Bienes - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Feb 2026.